Remission of Type 2 Diabetes With Lifestyle Intervention

Launched by UNIVERSITY OF SPLIT, SCHOOL OF MEDICINE · Jun 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether making significant lifestyle changes can help people with type 2 diabetes go into remission, meaning they can maintain healthy blood sugar levels without needing medication. The trial focuses on participants following a Mediterranean diet, which emphasizes fruits, vegetables, whole grains, and healthy fats, while also cutting back on calories. They will be encouraged to exercise daily and work on managing stress, all with the support of group counseling and workshops over six months. The researchers want to see if these changes can help participants lose more than 15 kilograms and if there are any side effects from this program.

To participate, individuals should have been diagnosed with type 2 diabetes within the last seven years and have a body mass index (BMI) between 27 and 45, which indicates obesity. However, people with certain health conditions, such as severe heart problems or those using specific diabetes medications, cannot join. If you qualify and choose to participate, you will receive personalized guidance and support to help you make these lifestyle changes, with follow-ups lasting up to 1.5 years to track your progress. This trial offers an exciting opportunity to potentially improve your health and manage diabetes more effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • type 2 diabetes diagnosis
• • incident cases or diagnosed not more than 7 years ago
• • body mass index of 27-45 kg/m²
• Exclusion Criteria:
• • mobility restriction
• • use of mobility aids
• • insulin therapy
• • HbA1c \>12%
• • TSH \>10 mU/L
• • heart failure (NYHA III, NYHA IV)
• • use of obesity pharmacotherapy (orlistat, GLP-1 receptor agonists, GLP-1/GIP dual agonists) for less than 6 months
• • weight loss greater than 5 kg in the last 6 months
• • chronic kidney disease and estimated glomerular filtration rate \<30 ml/min/1.73 m2
• • active treatment of proliferative diabetic retinopathy with anti-VEGF
• • heart attack or stroke in the past 1 year
• • active malignant disease diagnosed in the past 1 year
• • eating disorders
• • pregnancy or pregnancy planning
• • substance abuse
• • learning disabilities
• • acute episode of severe depression
• • current use of antipsychotics
• • food allergy